SLC1A3: A Potential Drug Target and Biomarker for Excitatory Amino Acid Transporter 1 (ISOFORM 2)

Target Name: SLC1A3

NCBI ID: G6507

SLC1A3

SLC1A3: A Potential Drug Target and Biomarker for Excitatory Amino Acid Transporter 1 (ISOFORM 2)

Excitatory amino acid transporter 1 (ISOFORM 2) is a protein that plays a crucial role in the regulation of neurotransmitter release in the central nervous system (CNS). It is expressed in various tissues, including the brain, and is involved in the transport of several amino acids, including glutamate, which is known for its role in neurotransmission. The SLC1A3 gene, which encodes this transporter, has been identified as a potential drug target and biomarker for several neurological disorders.

SLC1A3 gene and its function

SLC1A3 is a member of the solute carrier family 1 (SLC) and is responsible for the transport of excotatory amino acids, including glutamate, as well as other small molecules. The SLC1A3 gene has four exons, each of which encodes a unique protein isoform. SLC1A3 is expressed in various tissues, including the brain, and is involved in the regulation of neurotransmitter release and neurotransmission.

SLC1A3 function and its role in neurological disorders

SLC1A3 is involved in the regulation of neurotransmitter release, which is critical for the function of the nervous system. It is known to play a role in the regulation of glutamatergic neurotransmission, which is the majority of neurotransmission in the brain.

SLC1A3 is also involved in the regulation of neurotransmission in the peripheral nervous system (PNS), which is important for the function of the muscles and other tissues.

Dysregulation of SLC1A3 has been implicated in several neurological disorders, including epilepsy, schizophrenia, and neurodegenerative diseases. For example, studies have shown that individuals with the SLC1A3 gene are more likely to have epilepsy, and that individuals with certain genetic variants in SLC1A3 are at increased risk for developing schizophrenia (5,6).

SLC1A3 as a potential drug target

SLC1A3 is a protein that is involved in the regulation of neurotransmission, which makes it an attractive target for drug development. Several studies have shown that inhibition of SLC1A3 can reduce neurotransmission, which could be a potential therapeutic approach for treating neurological disorders.

One of the potential advantages of targeting SLC1A3 is that it is a transporter, which means that it can be targeted directly with small molecules, such as drugs. This is in contrast to some other proteins, such as ion channels, which are often difficult to target with small molecules due to their complexity.

Another potential advantage of targeting SLC1A3 is that it is involved in the regulation of multiple neurotransmitter systems, which makes it more versatile as a drug target. This means that targeting SLC1A3 could potentially be effective in treating a range of neurological disorders, rather than just one specific disorder.

SLC1A3 as a biomarker

In addition to its potential as a drug target, SLC1A3 is also a potential biomarker for several neurological disorders. The SLC1A3 gene has been shown to be involved in the regulation of neurotransmission, which could make it an attractive biomarker for neurological disorders.

For example, individuals with certain genetic variants in SLC1A3 have been shown to be at increased risk for developing schizophrenia, and brain imaging studies have shown that individuals with schizophrenia have lower levels of SLC1A3 than those without the disorder. Additionally, studies have shown that individuals with certain neurological disorders, such as epilepsy, have lower levels of SLC1A3 than those without the disorder.

SLC1A3 could also be used as a biomarker for other neurological disorders, such as neurodegenerative diseases, as SLC1A3 is known to be involved in the regulation of neurotransmission in these disorders.

Conclusion

SLC1A3 is a protein that is involved in the regulation of neurotransmission and has been implicated in several neurological disorders. As a potential drug target and biomarker, SLC1A3 is an attractive target for drug development and research into the underlying mechanisms of these disorders. Further studies are needed to fully understand the role of SLC1A3 in neurological disorders and to develop effective treatments.

Protein Name: Solute Carrier Family 1 Member 3

Functions: Sodium-dependent, high-affinity amino acid transporter that mediates the uptake of L-glutamate and also L-aspartate and D-aspartate (PubMed:7521911, PubMed:8123008, PubMed:20477940, PubMed:26690923, PubMed:28032905, PubMed:28424515). Functions as a symporter that transports one amino acid molecule together with two or three Na(+) ions and one proton, in parallel with the counter-transport of one K(+) ion (PubMed:20477940). Mediates Cl(-) flux that is not coupled to amino acid transport; this avoids the accumulation of negative charges due to aspartate and Na(+) symport (PubMed:20477940). Plays a redundant role in the rapid removal of released glutamate from the synaptic cleft, which is essential for terminating the postsynaptic action of glutamate (By similarity)

The "SLC1A3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC1A3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets